Head-to-head · free

Twist Bioscience vs UnitedHealth Group

TWST vs UNH — return on capital, cash generation, margins and balance sheet side by side.

TWST

2 / 6

measures where TWST leads

UNH

4 / 6

measures where UNH leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureTWST · FY2026UNH · FY2025
Revenue—$447.6B
Net income(130.2M)$12.1B
Revenue growth (yearly, multi-year)—11.7%
Free cash flow(89.0M)$16.1B
Free cash flow margin—3.6%
Net cash / (debt)—(54.0B)
ROIC—9.2%
Return on equity-16.4%12.9%
Gross margin50.7%18.5%
Operating margin-36.2%4.2%
Net debt / EBITDA1.64x2.32x

Figures are as reported by each company; latest fiscal year shown.

Where Twist Bioscience's cash went (FY2026)

Capital spending
$47.6M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TWST profile →

Where UnitedHealth Group's cash went (FY2025)

Capital spending
$3.6B
Buybacks
$5.5B
Dividends
$7.9B
Acquisitions
$4.5B
Net debt issued / (repaid)
$726.0M
Full UNH profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons